ALMS Therapeutics

ALMS Therapeutics was a biotechnology company focused on developing treatments for Alström syndrome, a rare genetic disorder, as well as more common metabolic conditions like obesity and type 2 diabetes. The company was founded based on research from The Jackson Laboratory regarding the ALMS1 gene and its influence on metabolic and fibrotic pathways. Its primary goal was to identify small molecule modulators that could mitigate the multi-organ dysfunction characteristic of the syndrome. Although the company is no longer active, its foundational research contributed to the understanding of ALMS1-related ciliopathies. The company was headquartered in Bar Harbor, Maine, and operated as a spin-off from academic research.